Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939523 · OUTCOME

ErbB Receptor Expression

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percent positive expression
Interval / dispersion
Standard Deviation
Time frame
at 6 months

What was measured

Mean percent positive expression of EGFR and ErbB2 will be tested on pathologic tumor specimens from subjects treated with lapatinib

Analysis population: Of the subjects who participated in the trial, only 3 had available tumor tissue to immunostain. Therefore, results could not be reported on the other subjects.

Groups in this outcome

Lapatinib

All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lapatinib3

Reported measurements

Source class 1
Values in percent positive expression · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Lapatinib00Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
Mean percent positive expression of EGFR and ErbB2 will be tested on pathologic tumor specimens from subjects treated with lapatinib
dispersion Type
Standard Deviation
groups
  1. description
    All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.
    id
    OG000
    title
    Lapatinib
param Type
MEAN
population Description
Of the subjects who participated in the trial, only 3 had available tumor tissue to immunostain. Therefore, results could not be reported on the other subjects.
reporting Status
POSTED
time Frame
at 6 months
title
ErbB Receptor Expression
type
SECONDARY
unit Of Measure
percent positive expression

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice